<DOC>
	<DOCNO>NCT02531698</DOCNO>
	<brief_summary>This study look new vaccine might prevent meningococcal disease , study immune response elicit vaccine give healthy young child . The study also look safety new vaccine well tolerate .</brief_summary>
	<brief_title>A Study Describe Immunogenicity , Safety , Tolerability Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine ( Bivalent rLP2086 ) Healthy Subjects Aged ≥24 Months &lt; 10 Years</brief_title>
	<detailed_description />
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Evidence personally sign date informed consent document ( ICD ) indicate subject 's parent ( ) /legal guardian inform pertinent aspect study . 2 . Parent ( ) /legal guardian subject willing able comply schedule visit , vaccine regimen , laboratory test , study procedure . 3 . Male female subject age ≥24 month &lt; 10 year time randomization , stratify equally age ( ≥24 month &lt; 4 year ≥4 year &lt; 10 year ) . 4 . Subject available entire study period subject 's parent ( ) /legal guardian reach telephone . 5 . Healthy subject determine medical history , physical examination , judgment investigator . 6 . Subject must receive vaccination relevant national immunization program ( NIP ) age group . 7 . Male female subject childbearing potential risk pregnancy must agree use highly effective method contraception throughout study . A subject childbearing potential , opinion investigator , he/she biologically capable child sexually active . 8 . Negative urine pregnancy test female subject biologically capable child . 1 . Previous vaccination meningococcal serogroup B vaccine . 2 . Subjects receive prior HAV vaccination . 3 . Contraindication vaccination HAV vaccine know latex allergy . 4 . Subjects receive allergen immunotherapy nonlicensed product subject receive allergen immunotherapy license product stable maintenance dos . 5 . A previous anaphylactic reaction vaccine vaccinerelated component . 6 . Bleeding diathesis condition associate prolonged bleeding time would contraindicate intramuscular injection . 7 . A know suspected defect immune system would prevent immune response vaccine , subject congenital acquire defect Bcell function , receive chronic systemic ( oral , intravenous , intramuscular ) corticosteroid therapy , receive immunosuppressive therapy . Subjects terminal complement deficiency may include . Additional detail provide study reference manual ( SRM ) . 8 . History microbiologically proven disease cause N meningitidis Neisseria gonorrhoeae . 9 . Significant neurological disorder history seizure ( exclude simple febrile seizure ) . 10 . Receipt blood product , include immunoglobulin , within 6 month first study vaccination . 11 . Current chronic use systemic antibiotic . 12 . Participation study involve investigational product ( ) /device ( ) ( Phases 14 ) within 28 day administration first study vaccination . Participation purely observational study acceptable . 13 . Any neuroinflammatory autoimmune condition , include limited transverse myelitis , uveitis , optic neuritis , multiple sclerosis . 14 . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study . 15 . Pregnant female subject , breastfeed female subject , male subject partner currently pregnant , male female subject childbearing potential unwilling unable use highly effective method contraception outline protocol duration study . 16 . Subjects child investigational site staff member directly involved conduct study family member , subject child site staff member otherwise supervised investigator , subject child Pfizer employee directly involve conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>24 Months</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>